IBDEI38E ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,51593,1,4,0)
 ;;=4^R63.3
 ;;^UTILITY(U,$J,358.3,51593,2)
 ;;=^5019541
 ;;^UTILITY(U,$J,358.3,51594,0)
 ;;=R63.4^^193^2509^33
 ;;^UTILITY(U,$J,358.3,51594,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51594,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,51594,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,51594,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,51595,0)
 ;;=R63.5^^193^2509^32
 ;;^UTILITY(U,$J,358.3,51595,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51595,1,3,0)
 ;;=3^Abnormal Weight Gain
 ;;^UTILITY(U,$J,358.3,51595,1,4,0)
 ;;=4^R63.5
 ;;^UTILITY(U,$J,358.3,51595,2)
 ;;=^5019543
 ;;^UTILITY(U,$J,358.3,51596,0)
 ;;=R64.^^193^2509^50
 ;;^UTILITY(U,$J,358.3,51596,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51596,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,51596,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,51596,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,51597,0)
 ;;=R68.3^^193^2509^55
 ;;^UTILITY(U,$J,358.3,51597,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51597,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,51597,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,51597,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,51598,0)
 ;;=R73.01^^193^2509^94
 ;;^UTILITY(U,$J,358.3,51598,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51598,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,51598,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,51598,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,51599,0)
 ;;=R73.02^^193^2509^95
 ;;^UTILITY(U,$J,358.3,51599,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51599,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,51599,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,51599,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,51600,0)
 ;;=R73.09^^193^2509^18
 ;;^UTILITY(U,$J,358.3,51600,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51600,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,51600,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,51600,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,51601,0)
 ;;=R73.9^^193^2509^89
 ;;^UTILITY(U,$J,358.3,51601,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51601,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,51601,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,51601,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,51602,0)
 ;;=R76.11^^193^2509^147
 ;;^UTILITY(U,$J,358.3,51602,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51602,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,51602,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,51602,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,51603,0)
 ;;=R79.1^^193^2509^3
 ;;^UTILITY(U,$J,358.3,51603,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51603,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,51603,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,51603,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,51604,0)
 ;;=R82.5^^193^2509^74
 ;;^UTILITY(U,$J,358.3,51604,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51604,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,51604,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,51604,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,51605,0)
 ;;=R82.6^^193^2509^30
 ;;^UTILITY(U,$J,358.3,51605,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51605,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,51605,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,51605,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,51606,0)
 ;;=R82.90^^193^2509^29
